Official Title A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)

Purpose

The purpose of this study is to evaluate the efficacy of ESK-001 

There may be a chance that you will be asked to come into the study site for unscheduled study visits that may include extra tests to assess for your safety.

The duration of the study will be a minimum of 28 weeks, if you participate in the long-term extension study, or 32 weeks if instead you enter the follow-up period. You will need to come to the study site at least 10 or 11 times respectively over this period. 

Could this study be right for you?

• Subject must have a diagnosis of plaque psoriasis for at least 6 months 
• Subjects must not have other immune-mediated conditions such as uveitis and inflammatory bowel disease (patients with psoriatic arthritis may participate) 
• Subject must be in good general health with no history of tuberculosis, cancer, HIV, hepatitis B or C
• Subjects must have no history of unstable cardiac disease (for example, unstable angina or rapid atrial fibrillation) or cardiac hospitalization within 3 months 
• Female subjects must not be pregnant or considering becoming pregnant for the duration of the study 

Age Range

18 years and up

Official Title The Development of Semantic Organization

Purpose

We are currently in the process of conducting a 5-year National Institutes of Health-funded longitudinal study on semantic and language development, specifically focusing on how children learn new words and understand their meanings. Our goal is to not only examine language learning but also how these processes evolve as children grow.

In this study, we will follow two hundred 4-year-old junior scientists as they participate in fun, interactive word-learning and language activities. Over the course of the study, participants will visit our lab twice a year, each lasting around 60-90 minutes (including breaks), to engage in a series of playful games with a research assistant designed to explore how children comprehend and retain new vocabulary. Additionally, your child will have the opportunity to wear a LENA recorder—a small, wearable device that tracks the number of words your child hears throughout the day, similar to a Fitbit but for words!

 

Could this study be right for you?

• Child must be monolingual
• Not born premature
• No developmental delays
• Can give a verbal response
• Normal to corrected vision

Age Range

4 - 4 years

Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)

Purpose

You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).

The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.

AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.

The overall goals of this study are:

• To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
• To measure if participants have changes in:
  • frequency of their seizures
  • how their seizures affect their life
  • how the human body takes up and removes AMT-260
• To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.

Could this study be right for you?

Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.

Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.

Age Range

18 - 65 years

Official Title Developing Rumination-Focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence (RuMeChange)

Purpose

We are conducting a study looking at how therapy strategies can help teenagers stay healthy, reduce rumination, or overthinking and worrying, and prevent depression relapse. If eligible, the teenager would complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI.

A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.

Could this study be right for you?

Inclusion Criteria:

• 14-17 years of age at enrollment
• Youth assent and parent consent

Exclusion Criteria:

• Metal braces, tattoos with metal
• Claustrophobia
• Current pregnancy

Age Range

14 - 17 years

Official Title A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa

Purpose

The purpose of this study is to evaluate the efficacy of lutikizumab

Could this study be right for you?

• Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
• Subject must have tried a 12-week (about 3 months) trial of oral antibiotics with inadequate improvement
• Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
• Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Adaptive Phase III Trial To Investigate Efficacy And Safety Of Viobelimab In The Treatment Of Ulcerative Pyoderma Gangrenosum

Purpose

This study aims to find out if a new investigational drug, vilobelimab (also called IFX-1) is safe and effective in treating pyoderma gangrenosum. 

The study will measure if the study drug closes the ulcers of your skin. It will also measure if the study drug improves the severity of your disease (according to the study doctor and according to you) and if it improves your pain and your quality of life. 

Could this study be right for you?

• Investigator confirmed clinical diagnosis of ulcerative pyoderma gangrenosum (PG). 

• Minimum of 1 PG ulcer (other than peristomal) which qualifies as the target ulcer 

  • Area of at least 5 cm2 at screening and baseline  
  • Circulated by intact skin  
  • Evaluable by at least 2-dimensional measurement 

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Multi-Center Comparative Effectiveness Study Of Spironolactone Versus Doxycycline Hyclate For The Treatment Of Acne In Women

Purpose

To determine whether spironolactone is non-inferior to the oral tetracycline-class antibiotic doxycycline hyclate in the treatment of acne in women 

Could this study be right for you?

• Assigned female at birth  

• Acne defined as at least 10 inflammatory papules or pustules 

• Not currently pregnant or planning to become pregnant  

• Willing to attest to abstinence or some form of contraception for the duration of the study (4 months). Approved options of birth control to use during the study include:  

  • Hormonal contraception (for example, birth control pills, injection, implant, transdermal patch, vaginal ring)  
  • Intrauterine device (IUD)  
  • Tubal ligation (tying your tubes)  
  • Partner with a vasectomy  
  • Male or female condom with spermicide  
  • Diaphragm with spermicide  
  • Cervical cap contraceptive sponge with spermicide  

Age Range

16 - 40 years

Official Title A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients

Purpose

The purpose of this study is to evaluate the efficacy of minoxidil.

Could this study be right for you?

• Subjects must have a diagnosis of breast cancer stages I-IV
• Subjects must have hair loss while on endocrine therapy (i.e., tamoxifen or an aromatase inhibitor such as anastrozole)
• Subjects must not be on chemotherapy or have been on chemotherapy within 2 years
• Subjects must not have tried oral or topical minoxidil or spironolactone previously
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study

Age Range

18 - 70 years

Official Title A Multicenter Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy

Purpose

• Subject must have a diagnosis of cutaneous lupus erythematosus 

• Subject must have tried antimalarial treatment (i.e., hydroxychloroquine, quinacrine, or chloroquine) for at least 12 weeks (about 3 months) or was unable to tolerate antimalarial treatment due to side effects 

• Subject must be in good general health with no history of tuberculosis, cancer, HIV, or hepatitis B or C 

• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study 

Could this study be right for you?

• Subject must have a diagnosis of cutaneous lupus erythematosus
• Subject must have tried antimalarial treatment (i.e., hydroxychloroquine, quinacrine, or chloroquine) for at least 12 weeks (about 3 months) or was unable to tolerate antimalarial treatment due to side effects
• Subject must be in good general health with no history of tuberculosis, cancer, HIV, or hepatitis B or C
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study

Age Range

18 - 70 years

Official Title An Examination of Culturally Responsive, Inclusive, and Socially Just Practices Parent Feedback

Purpose

The research study will examine parents’ - or a child’s primary caregiver - perspectives on an online professional development (PD) training for teachers, targeting early care and education (ECE) teachers’ use of culturally responsive, inclusive, and socially just practices. Parents of young children will be recruited to review the online PD course and complete surveys about the course. A subset of participants will participate in a focus group to share their feedback on the course.

Could this study be right for you?

Parent or caregiver to a child who:

• Is between 3 and 5 years old
• Is identified as Black/African American
• Attends a center-based early care and education program (pre-kindergarten, Head Start, child care, preschool, etc.)

Age Range

17 - 99 years

Official Title Visuomotor skills assessed with different sports vision-related devices

Purpose

The purpose of this project is to determine whether performance correlates between different hand-eye coordination testing and training devices. Two of these devices require the participant to push lighted buttons on a wall-mounted board as fast as possible. The other device requires the participant to push a button at the same time that a (simulated) approaching object arrives.

 

Could this study be right for you?

• Visual acuity of 20/20 in each eye
• Stereoacuity (depth perception) of 60 seconds of arc
• No eye turn (strabismus) in left, right, or straight ahead gaze

Age Range

18 - 40 years

Official Title Progression of Social Cognitive Deficits in Mid- and Late-Life Schizophrenia Spectrum Disorders

Purpose

This research is being done to investigate the effects of age on social cognition in schizophrenia spectrum disorder. The study also hopes to examine potential neural bases of social cognition. The findings of the research will help develop effective treatment strategies by identifying who, when, and how to intervene.

Could this study be right for you?

Patients:

• Diagnosis of a schizophrenia spectrum disorder (includes schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, schizophreniform disorder, unspecified or other-specified psychotic disorders)

Healthy Controls:

• No history of any psychotic disorder
• No psychiatric diagnosis in the last 5 years
• Not taking psychotropic medication

 

Age Range

35 - 75 years